Description
Recombinant Mouse TNFSF7/CD70 Protein (Fc Tag)(Active) | PKSM040343 | Gentaur US, UK & Europe Disrtribition
Synonyms: Cd27l;CD27LG;Tnfsf7
Active Protein: Active protein
Activity: A DNA sequence encoding the mouse Cd70 (NP_035747.1) (Gln47-Pro195) was expressed with the Fc region of mouse IgG1 at the N-terminus.
Protein Construction: A DNA sequence encoding the mouse Cd70 (NP_035747.1) (Gln47-Pro195) was expressed with the Fc region of mouse IgG1 at the N-terminus.
Fusion Tag: N-Fc
Species: Mouse
Expressed Host: HEK293 Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 95 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 43.1 kDa
Formulation: Lyophilized from sterile PBS, pH 7.4
Reconstitution: Please refer to the printed manual for detailed information.
Background: CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.Immune CheckpointImmune Checkpoint ProteinsImmune Checkpoint Targets Co-stimulatory Immune Checkpoint Targets Immunotherapy Cancer Immunotherapy Targeted Therapy
Research Area: N/A
